Ultragenyx Pharmaceutical Inc.
Symbol: RARE (NASDAQ)
33.41
▲ (0.81%) 0.270
Company Description:
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Key Stats
- Today's Open: $33.21
- Today's High: $34.1
- Today's Low: $32.942
- Today's Volume: 1.00M
- Yesterday Close: $33.14
- Yesterday High: $34.33
- Yesterday Low: $33.1
- Yesterday Volume: 934.49K
- Last Min Volume: 1
- Last Min High: $33.464
- Last Min Low: $33.41
- Last Min VWAP: $33.464
Company Profile
- Name: Ultragenyx Pharmaceutical Inc.
- Website: https://www.ultragenyx.com
- Listed Date: 2014-01-31
- Location: NOVATO, CA
- Market Status: Active
- CIK Number: 0001515673
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.29B
- Round Lot: 100
- Outstanding Shares: 96.37M
- Asset Type: CS
RECENT FILINGS FOR RARE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-14 | 4 | View |
| 2025-09-19 | 4 | View |
| 2025-09-12 | 144 | View |
| 2025-09-12 | 4 | View |
| 2025-09-08 | 8-K | View |
| 2025-09-08 | 4 | View |
| 2025-08-18 | 8-K | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-05 | 8-K | View |
| 2025-07-31 | 8-K | View |
| 2025-07-18 | S-8 | View |
| 2025-07-11 | 8-K | View |
| 2025-07-09 | 8-K | View |
| 2025-06-27 | 8-K | View |
| 2025-06-23 | 4 | View |
| 2025-06-20 | 144 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
Latest News on RARE